Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations
Monday, August 17, 2020 - 21:00
in Health & Medicine
In a Phase II trial a combination targeted therapy achieved a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.